Nanyang, NVIDIA, HPE, Equinix Unite for AI Drug Discovery

Fischer Medical Ventures Ltd (FMV) through its closely associated company Nanyang Biologics (NYB) shares the glory of securing an exceptional partnership with NVIDIA, Hewlett Packard Enterprise (HPE), and Equinix, top global technology leaders, to co-create VECURA, an advanced AI-powered drug discovery platform.

VECURA maps out the possibilities of “AI-as-a-Service” aiming to make the Federal Food Administration (FDA) cycle, which normally takes 10 to 12 years, drop to just a few hours. A melting pot in Singapore draws on NYB’s exclusive catalog of millions of natural compounds to go with AI modeling, high-end computing, and cloud infrastructure supplied by the four partners from different parts of the world. They want to nurture the first and foremost largest AI-curated compound library, which in turn would shorten the time of preparation of next-generation therapeutics.

This platform uses AI, machine learning, and virtual screening to re-engineer the drug discovery process in which the users had to wait for more than a decade and spend a fortune in traditional ways. The task of extracting pharmaceutical compounds from nature’s tropical kingdom and integrating advanced metagenomics and metaproteomics analysis is handled by VECURA in a rapid manner thus enabling the virtual screening. The coming of age of the platform is likely to cut the expenditures, time to drugs, as well as opening the door to revolutionary, individualized, and nature-derived pharmaceuticals.

Also Read: Govt Rolls Out Rs 5,000 Cr Plan to Boost Pharma R&D

While drug discovery remains a priority at NYB, the company is unlocking the immense potential of VECURA to reach the nutraceuticals universe. FMV will take the lead in global distribution, thus making it possible for the health care providers in numerous regions to have easy access to these cutting-edge solutions for the health care market.